JOURNAL OF DRUG TARGETING

metrics 2024

Fostering collaboration for pharmaceutical excellence.

Introduction

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.

Metrics 2024

SCIMAGO Journal Rank0.85
Journal Impact Factor4.30
Journal Impact Factor (5 years)4.60
H-Index107
Journal IF Without Self4.30
Eigen Factor0.00
Normal Eigen Factor0.63
Influence0.73
Immediacy Index0.60
Cited Half Life7.00
Citing Half Life5.70
JCI0.94
Total Documents1999
WOS Total Citations5066
SCIMAGO Total Citations19207
SCIMAGO SELF Citations561
Scopus Journal Rank0.85
Cites / Document (2 Years)5.36
Cites / Document (3 Years)4.87
Cites / Document (4 Years)5.06

Metrics History

Rank 2024

Scopus

Pharmaceutical Science in Pharmacology, Toxicology and Pharmaceutics
Rank #23/183
Percentile 87.43
Quartile Q1

IF (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 69/354
Percentile 80.60
Quartile Q1

JCI (Web Of Science)

PHARMACOLOGY & PHARMACY
Rank 94/354
Percentile 73.45
Quartile Q2

Quartile History

Similar Journals

BIOMATERIALS

Pioneering Innovations in Bioengineering and Beyond
Publisher: ELSEVIER SCI LTDISSN: 0142-9612Frequency: 36 issues/year

BIOMATERIALS, published by Elsevier Science Ltd, is a premier academic journal dedicated to the interdisciplinary field of biomaterials research. With an impressive impact factor, it ranks in the Q1 quartile across multiple categories including Bioengineering, Biomaterials, and Biophysics, showcasing its significance in advancing scientific knowledge. Established in 1980 and set to converge its discussions through 2025, this journal provides a critical platform for researchers and professionals to disseminate their findings on the development, application, and performance of biomaterials. The journal covers a wide range of topics, from the mechanics of materials to nanotechnology, and is highly regarded with top Scopus rankings in essential categories, including an exceptional position within the 99th percentile for Biophysics. Although not an open access journal, BIOMATERIALS remains vital for students and established researchers alike, ensuring accessibility to groundbreaking research in the field. Engage with cutting-edge studies that pave the way for innovative applications in medicine, engineering, and beyond.

Materials Science & Engineering C-Materials for Biological Applications

Connecting materials science with biological advancements.
Publisher: ELSEVIERISSN: 0928-4931Frequency: 12 issues/year

Materials Science & Engineering C-Materials for Biological Applications is a premier journal published by ELSEVIER, dedicated to advancing the field of biomaterials through interdisciplinary research. With a robust ISSN of 0928-4931, this journal has made its mark in the realms of Chemical Engineering and Materials Science, achieving impressive Scopus rankings within its categories, namely Rank #16/151 in Bioengineering (89th percentile) and Rank #13/112 in Biomaterials (88th percentile). Although the journal's coverage in Scopus has been discontinued since 2021, it remains a critical resource for researchers, professionals, and students eager to explore innovative materials and their applications in biological contexts. The journal’s open access policy enhances its accessibility, fostering a global exchange of knowledge and inspiring future advancements in the field of materials science.

Nanomedicine

Advancing the Future of Medicine through Nanotechnology
Publisher: FUTURE MEDICINE LTDISSN: 1743-5889Frequency: 30 issues/year

Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

Current Drug Delivery

Exploring the forefront of therapeutic advancements.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1567-2018Frequency: 10 issues/year

Current Drug Delivery, published by Bentham Science Publishers Ltd, serves as a vital platform for advancing the field of pharmaceutical sciences. With an ISSN of 1567-2018 and an E-ISSN of 1875-5704, this esteemed journal focuses on all aspects of drug delivery systems, encompassing innovative research and developments that aim to improve therapeutics and patient outcomes. Operating from the United Arab Emirates, it has an impressive standing reflected in its 2023 Q2 ranking in Pharmaceutical Sciences and a notable position within the 62nd percentile in Scopus’s Pharmacology, Toxicology, and Pharmaceutics category. The journal not only acts as an essential resource for researchers and professionals but it also encourages the dissemination of knowledge among students and budding scientists. With the latest articles and reviews converging from 2004 to 2024, Current Drug Delivery remains committed to offering high-quality content that enhances understanding and sparks innovation in drug delivery mechanisms.

Advanced Pharmaceutical Bulletin

Empowering Knowledge in Pharmaceutical Sciences
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5881Frequency: 2 issues/year

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

Advanced NanoBiomed Research

Transforming Ideas into Biomedical Solutions
Publisher: WILEY-V C H VERLAG GMBHISSN: 2699-9307Frequency: 12 issues/year

Advanced NanoBiomed Research is a pioneering open-access journal committed to advancing the interdisciplinary field of nanobiotechnology, published by WILEY-V C H VERLAG GMBH. Since its inception in 2021, this journal has provided a platform for innovative research that bridges the gap between engineering, medicine, and materials science. With impressive rankings in Scopus, positioning it within the top quartiles of various categories, Advanced NanoBiomed Research aims to disseminate high-quality research that contributes to the understanding and application of nanomaterials in biomedical contexts. As it encompasses a wide scope—from applied microbiology to biomaterials—it serves as an essential resource for researchers, professionals, and students eager to explore the cutting-edge developments in the field. The journal promotes a collaborative environment where emerging ideas can flourish, ensuring that vital advancements in nanobiomedicine can be shared and built upon within the scientific community.

Therapeutic Delivery

Transforming Therapeutics Through Open Access Knowledge
Publisher: Newlands Press LtdISSN: 2041-5990Frequency: 12 issues/year

Therapeutic Delivery is a prestigious journal dedicated to advancing the field of Pharmaceutical Science, published by Newlands Press Ltd. Since its inception in 2010, this journal has become a vital resource for researchers and professionals alike, focusing on innovative drug delivery systems and therapeutic approaches that enhance patient care. With an impressive impact factor reflective of its credibility and scholarly influence, Therapeutic Delivery is currently ranked in the Q2 quartile and placed at Rank #64 out of 183 in the realm of Pharmacology, Toxicology, and Pharmaceutics, showcasing its prominence in the field. The journal operates with an Open Access format, ensuring that groundbreaking research is readily available to a global audience. Based in the United Kingdom, it publishes comprehensive articles that cover a wide spectrum of topics within pharmaceutical sciences, from molecular mechanisms to clinical applications, thus catering to both academic and professional readerships. Researchers, students, and industry professionals will find Therapeutic Delivery an invaluable platform for sharing insights and fostering advancements in therapeutic methodologies.

Cancer Nanotechnology

Transforming Oncology with Cutting-Edge Nanotech Solutions
Publisher: SPRINGER WIENISSN: 1868-6958Frequency: 1 issue/year

Cancer Nanotechnology is a cutting-edge peer-reviewed journal dedicated to advancing the field of cancer research through innovative nanotechnology applications. Published by SPRINGER WIEN, this open-access journal, established in 2010, provides a vital platform for the dissemination of high-quality research with a focus on the intersection of nanotechnology, oncology, and biomedical engineering. With a commitment to promoting accessibility and fostering collaboration, Cancer Nanotechnology has gained impressive rankings within specialized categories, including Q2 in Biomedical Engineering and Pharmaceutical Science. The journal's rigorous selection process ensures that only the most impactful studies reach its audience, making it a must-read for researchers, professionals, and students eager to explore the latest advancements and methodologies in cancer treatment. With its scope encompassing critical topics that bridge multiple disciplines—including physical chemistry and toxicology—Cancer Nanotechnology positions itself as an influential resource for shaping the future of cancer therapies.

ADVANCED DRUG DELIVERY REVIEWS

Transforming Pharmaceutical Frontiers.
Publisher: ELSEVIERISSN: 0169-409XFrequency: 12 issues/year

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

BIOCONJUGATE CHEMISTRY

Exploring the Synergy of Chemistry and Biology
Publisher: AMER CHEMICAL SOCISSN: 1043-1802Frequency: 12 issues/year

BIOCONJUGATE CHEMISTRY, published by the American Chemical Society, is an esteemed journal that has been at the forefront of innovative research since its inception in 1973. With an impressive impact factor and a robust reputation, it occupies the Q1 category in fields such as Bioengineering, Biomedical Engineering, Biotechnology, Organic Chemistry, Pharmaceutical Science, and Pharmacology, making it a vital resource for researchers, professionals, and students alike. Its rigorous peer-reviewed articles explore the diverse and rapidly advancing realm of bioconjugate chemistry, offering pivotal insights into applications that bridge chemistry with biology. Though not an Open Access journal, it ensures wide distribution through various academic platforms, making critical research accessible to the scientific community. With its high Scopus rankings, specifically Rank #23 in Organic Chemistry and Rank #25 in Pharmaceutical Science, the journal exemplifies excellence in scientific communication and serves as an essential platform for the dissemination of groundbreaking findings in the interdisciplinary field of bioconjugates.